USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB Swati Bharadwaj Hyderabad: Dr ...

Dr. Reddy’s Laboratories (RDY) announced on Friday that the U.S. Food and Drug Administration has accepted for review its ...

The US Food and Drug Administration (USFDA) has greenlit Dr Reddy's Biologics License Application for a proposed biosimilar to Orencia (abatacept).

A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...

Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

The global biosimilar contract manufacturing market size was valued at USD 9.22 billion in 2025 and is predicted to hit ...

The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...

Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Zydus Lifesciences launches Anyra, India’s first indigenous biosimilar of Aflibercept, aiming to enhance affordable access to advanced diabetic eye-care treatments and strengthen the country’s ...